Improving Health of Mitochondria May Be a Viable ALS Treatment Option

The amyotrophic lateral sclerosis (ALS) drug Rilutek (riluzole) prevents neuronal cell death in part by acting on mitochondria, suggesting that treatment approaches that target the way mitochondria signal within cells may be a viable approach to treating ALS. The study, “Riluzole But Not Melatonin Ameliorates Acute Motor…

Flex Pharma said it plans to prioritize developing its clinical programs in neurological diseases, including amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and peripheral neuropathies like Charcot-Marie Tooth (CMT). One or two proof-of-concept, Phase 2 clinical trials are planned for this year in the United States to evaluate the company’s transient receptor…

This Facebook video from Science Nature Page shares a little bit of information about the wearable robot hand that has been designed to help people who have lost function of their hands. Read about six ALS therapies designed to improve quality of life.  The device could help people who…

The advancements in both technology and medicine means that managing symptoms of ALS is now easier than ever before. Doctors are able to make patients much more comfortable and improve their quality of life. There are various areas of medical management needed for people with amyotrophic lateral sclerosis (ALS) and we’ve listed…

Cognitively healthy amyotrophic lateral sclerosis (ALS) patients have brain damage that mirrors their subtype of the disease, researchers have learned, and patients with bulbar-onset ALS have more widespread brain tissue loss — a finding that could explain why the patients fare worse than others. In their study, “Relationship between…

Stephen Hawking is, without a doubt, the most famous person with amyotrophic lateral sclerosis (ALS). He’s so incredibly famous for two main reasons: firstly, he’s a brilliant scientist. He’s changed the world’s understanding of space, made history with his papers on the Big Bang Theory and wrote a bestselling book A Brief History…

The European Union’s Joint Programme — Neurodegenerative Disease Research (JPND) invites researchers in 20 countries to work together in conducting and analyzing projects into various neurodegenerative diseases, so that they might identify common links and underlying mechanisms. Such “pathway ” analyses, the JPND said in a release, “could lead…